关键词:

新辅助化疗, 肿瘤异质性, 三阴性乳腺癌, 基因

Abstract:

The clinical manifestations, pathological characteristics, neoadjuvant treatment plan, heterogeneity changes in tumor genes, Miller-Payne (MP) classification, and surgery and other treatment plans of a patient with refractory locally advanced triple-negative breast cancer admitted to General Surgery, Tianjin Medical University General Hospital were analyzed. A specific subgroup of refractory locally advanced triple-negative breast cancer patients experiences molecular subtype conversion and molecular gene heterogeneity changes after neoadjuvant chemotherapy, which enhances the sensitivity of triple-negative breast cancer patients to conventional resistant chemotherapy regimens and improves their final comprehensive treatment decision-making. This kind of disease is relatively rare in actual clinical treatment, and it is easy for certain groups of people to be misdiagnosed and delayed in treatment. It helps to gradually form a consensus on treatment to summarize this kind of cases.

Key words:

Neoadjuvant chemotherapy, Tumor gene heterogeneity, Triple-negative breast cancer, Gene